Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8791154 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(9 years from now) | |
US9533053 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(9 years from now) |
Market Authorisation Date: 30 January, 2015
Treatment: Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
6
United States
4
Korea, Republic of
2
China
2
European Union
1
South Africa
1
Mexico
1
Australia
1
Hong Kong
1
Russia
1
Uruguay
1
Argentina
1
Colombia
1
Brazil
1
Spain
1
Chile
1
Taiwan, Province of China
1
Ukraine
1
Japan
1
Canada
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8399508 | NOVARTIS | Olopatadine formulations for topical nasal administration |
Sep, 2022
(6 months ago) | |
US7977376 | NOVARTIS | Olopatadine formulations for topical nasal administration |
Feb, 2023
(a month ago) | |
US8399508
(Pediatric) | NOVARTIS | Olopatadine formulations for topical nasal administration |
Mar, 2023
(10 days ago) | |
US7977376
(Pediatric) | NOVARTIS | Olopatadine formulations for topical nasal administration |
Aug, 2023
(4 months from now) |
Market Authorisation Date: 15 April, 2008
Treatment: Allergic rhinitis
Dosage: SPRAY, METERED;NASAL
6
United States
5
Japan
1
South Africa
1
Denmark
1
Austria
1
Mexico
1
Australia
1
Hong Kong
1
Germany
1
Argentina
1
Brazil
1
Portugal
1
GC
1
Spain
1
Korea, Republic of
1
Poland
1
Taiwan, Province of China
1
China
1
Canada
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic